SUMITOMO PHARMA CO LTD
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Public, Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- $1.8B
A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2015-02-09
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT02358395
- Locations
- π―π΅
4 Sites, Tokyo,etc, Japan
A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT02354898
- Locations
- π―π΅
5 Sites, Chiba, Etc., Japan
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT02347917
- Locations
- π―π΅
National Cancer Center Hospital, Tokyo, Japan
π―π΅National Cancer Center Hospital East, Chiba, Japan
Long-term Study of DSP-5423P in Patients With Schizophrenia
- First Posted Date
- 2015-01-12
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT02335658
- Locations
- π―π΅
38 Sites, Tokyo, Japan
Confirmatory Study of DSP-5423P in Patients With Schizophrenia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 580
- Registration Number
- NCT02287584
- Locations
- π―π΅
53 Sites, Tokyo Etc., Japan
π¨π³3 Sites, Beijing, Etc., China
π°π·7 Sites, Seoul, Etc., Korea, Republic of
A Phase III Study of SM-13496 in Patients With Bipolar I Depression.
- First Posted Date
- 2013-11-18
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 525
- Registration Number
- NCT01986101
- Locations
- π―π΅
Japan 76 sites, Tokyo, Japan
π±πΉLithuania 3 sites, Kaunas, Lithuania
π²πΎMalaysia 5 sites, Kuala Lumpur, Malaysia
A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.
- First Posted Date
- 2013-11-18
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 495
- Registration Number
- NCT01986114
- Locations
- πΊπ¦
Ukraine 9 sites, Kiev, Ukraine
πΈπ°Slovakia 5 sites, Zilina, Slovakia
π²πΎMalaysia 5 sites, Kuala Lumpur, Malaysia
A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 457
- Registration Number
- NCT01614899
- Locations
- π¨π³
14 Sites, Taipei, Etc, Taiwan
π―π΅69 Sites, Tokyo, Etc, Japan
π°π·22 Sites, Seoul, Etc, Korea, Republic of
Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 284
- Registration Number
- NCT01614912
- Locations
- π²πΎ
10 Sites, Kuala Lumpur, Etc, Malaysia
π―π΅69 Sites, Tokyo, Etc, Japan
π°π·22 Sites, Seoul, Etc, Korea, Republic of
Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer
- First Posted Date
- 2010-09-22
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 202
- Registration Number
- NCT01207011
- Locations
- π―π΅
32 Sites, Multiple Locations, Japan
Β© Copyright 2024. All Rights Reserved by MedPath